Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years

Hospices Civils de Lyon2,055 enrolled

Overview

Azithromycin is an antibiotic currently prescribed continuously in cystic fibrosis patients. It was shown that this treatment taken every day or every week for 12 months, can improve the respiratory state of patients. From the second year of treatment, it would appear there is more profit to continue such treatment. The main objective is to study the association between continuous use of azithromycin and lung function measured by Forced expiratory volume in one second (FEV1), after two years of treatment.

Study Type

OBSERVATIONAL

Enrollment

2,055

Conditions

Cystic Fibrosis

Interventions

AzithromycinDRUG

Eligibility

Sex: ALLMin age: 7 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Cystic Fibrosis (whatever the genetic form) * Age ≥ 8 years * FEV ≥ 30% the year of azithromycin (N0) * Continuous treatment with azithromycin for at least 2 years. Exclusion Criteria: \-

Locations (1)

Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet

Pierre-Bénite, France

Outcomes

Primary Outcomes

Forced expiratory volume in one second (FEV1).

Time frame: yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin

Secondary Outcomes

Body Mass Index (BMI)

Time frame: yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin

Number of IV antibiotics cures

Time frame: yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin

Pseudomonas aeruginosa colonization

Time frame: yearly recorded, 2 years before initiation of Azithromycin and 4 years after initiation of Azithromycin

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.